The system is expected to strengthen into a tropical storm by the end of the day and continue strengthening if it remains ...

Novo Nordisk NVO is expected to beat estimates when it reports third-quarter 2024 results on Nov. 6, before the opening bell.

Wegovy may significantly reduce hospital admissions for any cause and overall length of stay, according to a new analysis of data from Novo Nordisk's phase 3 SELECT trial. Compared to patients ...

Wegovy is a weight loss medication that you can only get with a prescription from a licensed healthcare professional. Learn more about who is eligible and what to expect at your initial ...

SAN ANTONIO — Treatment with once-weekly semaglutide 2.4 mg (Wegovy) significantly reduced hospital admissions for all causes — not just cardiac — and overall hospitalization time in people ...

BIGBANG’s G-Dragon is back—and topping music charts across the globe! On October 31 at 6 p.m. KST, G-Dragon made his long-awaited solo return with his new pre-release single “POWER.” ...

People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss medication Wegovy -- had a nearly 14% decrease in their body weight after ...

Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its status as a weight-loss medicine that can treat and prevent several ...

Once-weekly, subcutaneous semaglutide 2.4 mg is marketed under the brand name Wegovy. Part 1 of the ESSENCE trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology ...

Novo Nordisk’s weight loss drug Wegovy helped people with a fatty liver disease called MASH experience improvements in liver scarring and achieve symptom resolution, results the company sees as ...